Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psyched：1亿美元用于摇头丸疗法、弗吉尼亚州基金、2024年观察名单、改革更新等
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
迷幻药开发商获得1亿美元的A轮融资，将支持MDMA批准治疗创伤后应激障碍
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).
作为迷幻研究多学科协会（MAPS）的全资子公司成立十年后，MAPS公益公司已通过A轮私募股票出售获得了超过1亿美元的融资。这笔资金将支持其申请监管部门批准出售摇头丸（也称为摇头丸）作为创伤后应激障碍（PTSD）治疗药物的最后阶段。
MAPS has incubated the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application...
MAPS已经孵化了唯一一个成功完成两项3期研究...
登录免费看全文
登录/注册